@entity37934 to increased serum concentrations of @entity1255 (Hcy), which is known as @entity3562 ( @entity3562 ), is associated with @entity79 . Although, Hcy accumulates collagen in bone and contribute to decrease in bone strength. The mechanism of Hcy induced @entity604 and remodeling is unclear. Therefore, the present study was aimed to determine the role of @entity1501 (FA) in genetically @entity3562 -associated @entity551 and remodeling. Wild type (WT) and @entity3959 -b-synthase heterozygous (CBS+/-) @entity19 were used in this study and supplemented with or without FA (300   mg/kg, Hcy reducing agent) in drinking water for 6 weeks. The tibial bone blood flow was measured by laser Doppler and ultrasonic flow probe method. The tibial bone density (BD) was assessed by dual energy X-ray absorptiometry. The bone homogenates were analyzed for oxidative stress, @entity14856 as oxidative marker and @entity15052 ( @entity15052 ) as anti-oxidant marker, bone remodeling ( @entity1235 ) and bio-availability of @entity842 (eNOS/ @entity13633 /NO) by Western blot method. The results suggested that there was decrease in tibial blood flow in CBS+/- @entity19 . The BD was also reduced in CBS+/- @entity19 . There was an increase in @entity14856 , @entity13633 , @entity1235 protein as well as @entity1235 activity in CBS+/- @entity19 and decrease in @entity15052 , eNOS protein levels, in part by decreasing NO bio-availability in CBS+/- @entity19 . Interestingly, these effects were ameliorated by FA and suggested that FA supplementation may have therapeutic potential against genetically @entity3562 induced @entity604 .

@entity1255 mediated @entity551 and remodeling: role of XXXX .

@entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid'] @entity14856 :: ('50490(Tax:10090)', 'Gene') :: ['NOX-4'] @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine'] @entity37934 :: ('MESH:C562799', 'Disease') :: ['Deficiencies in folate lead'] @entity3959 :: ('MESH:D003540', 'Chemical') :: ['cystathionine'] @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disorders'] @entity1235 :: ('17395(Tax:10090)', 'Gene') :: ['MMP-9'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity13633 :: ('18126(Tax:10090)', 'Gene') :: ['iNOS'] @entity15052 :: ('22166(Tax:10090)', 'Gene') :: ['thioredoxin-1', 'Trx-1'] @entity3562 :: ('MESH:D020138', 'Disease') :: ['HHcy', 'hyperhomocysteinemia'] @entity551 :: ('MESH:D007022', 'Disease') :: ['decrease in bone blood flow']
@entity1501 :: (MESH:D005492,Chemical) :: ['folic acid']
